Luoxin Pharmaceuticals Group Stock Co., Ltd.

SZSE:002793 Stock Report

Market Cap: CN¥4.9b

Luoxin Pharmaceuticals Group Stock Past Earnings Performance

Past criteria checks 0/6

Luoxin Pharmaceuticals Group Stock's earnings have been declining at an average annual rate of -61.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 26.3% per year.

Key information

-61.3%

Earnings growth rate

-64.1%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-26.3%
Return on equity-37.1%
Net Margin-28.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Luoxin Pharmaceuticals Group Stock Co., Ltd. (SZSE:002793) Held Back By Insufficient Growth Even After Shares Climb 41%

Oct 21
Luoxin Pharmaceuticals Group Stock Co., Ltd. (SZSE:002793) Held Back By Insufficient Growth Even After Shares Climb 41%

Why Investors Shouldn't Be Surprised By Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Low P/S

Aug 23
Why Investors Shouldn't Be Surprised By Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Low P/S

Luoxin Pharmaceuticals Group Stock (SZSE:002793) Is Making Moderate Use Of Debt

Jun 25
Luoxin Pharmaceuticals Group Stock (SZSE:002793) Is Making Moderate Use Of Debt

Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Price Is Right But Growth Is Lacking After Shares Rocket 25%

May 21
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Subdued Growth No Barrier To Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Price

Feb 28
Subdued Growth No Barrier To Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Price

Revenue & Expenses Breakdown

How Luoxin Pharmaceuticals Group Stock makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SZSE:002793 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,418-6971,42070
30 Jun 242,368-6231,30580
31 Mar 242,390-6081,32889
31 Dec 232,364-6611,393112
30 Sep 231,644-9571,316124
30 Jun 231,700-1,2341,317143
31 Mar 232,073-1,3971,481187
01 Jan 233,588-1,2252,249205
30 Sep 225,155-5282,391267
30 Jun 226,177-92,587299
31 Mar 226,9123302,698313
01 Jan 226,4784062,331321
30 Sep 216,8304142,590324
30 Jun 216,8604032,746326
31 Mar 216,5643662,693329
31 Dec 206,0963212,403361
30 Sep 206,3205772,525360
30 Jun 206,3385552,624382
31 Mar 207,0626203,218405
31 Dec 197,5896343,611420
30 Sep 198,5026294,349524
30 Jun 199,6807525,221621
31 Mar 197,7826114,111522
31 Dec 186,2115123,297420
31 Mar 174,3873453,0150
31 Dec 164,1183792,7740
30 Sep 163,8884162,4610
30 Jun 163,7874682,2600
31 Mar 163,7675022,0950
31 Dec 153,6114932,0130
30 Sep 153,3564741,7970
30 Jun 153,0574461,6630
31 Mar 152,9004301,6300
31 Dec 142,7674441,4700
30 Sep 142,7574021,4420
30 Jun 142,7244111,3290
31 Mar 142,5544201,2040

Quality Earnings: 002793 is currently unprofitable.

Growing Profit Margin: 002793 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 002793 is unprofitable, and losses have increased over the past 5 years at a rate of 61.3% per year.

Accelerating Growth: Unable to compare 002793's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 002793 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).

Return on Equity

High ROE: 002793 has a negative Return on Equity (-37.14%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 13:15
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Luoxin Pharmaceuticals Group Stock Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jayaprabha DhavaleVirtua Research Inc.